ライフサイエンスコーパス: Calmette

1 Bacille Calmette Guerin-vaccinated children were more likely to

2 Bacille Calmette-Guerin (BCG) is an attenuated strain of Mycobac

3 Bacille Calmette-Guerin (BCG) vaccination has been suggested to

4 Bacille Calmette-Guerin (BCG) vaccination induces a marked incre

5 Bacille Calmette-Guerin (BCG) vaccination may induce persistent

6 Bacille Calmette-Guerin (BCG) vaccination, known to induce parti

7 Bacille Calmette-Guerin (BCG), an attenuated strain of Mycobacte

8 Bacille Calmette-Guerin is the most effective therapy for carcin

9 Bacille Calmette-Guerin vaccination, tuberculosis prevalence in

10 During 1986-1989, a bacille Calmette-Guerin (BCG) vaccine trial was carried out in n

11 e show in this article that although bacille Calmette-Guerin controlled M. tuberculosis growth for 7

12 odeficiency virus (HIV)-infected and bacille Calmette-Guerin (BCG)-immunized adults with CD4 cell cou

13 medical illness, isoniazid use, and bacille Calmette-Guerin strain did not substantially affect vacc

14 y to nontuberculous mycobacteria and bacille Calmette-Guerin vaccination may account for a proportion

15 rain of Mycobacterium bovis known as bacille Calmette-Guerin (BCG) has been widely used as a vaccine

16 Live attenuated Bacille Calmette-Guerin (BCG) bacillus is the only licensed vacc

17 erium tuberculosis vaccines to boost bacille Calmette-Guerin or for those who cannot be immunized wit

18 osis Ag 85A (M.85A), strongly boosts bacille Calmette-Guerin (BCG)-induced Ag 85A specific CD4(+) and

19 strict growth of Mycobacterium bovis bacille Calmette Guerin and Mycobacterium tuberculosis was impai

20 AT)-6, that are absent from M. bovis bacille Calmette-Guerin (BCG) and most environmental mycobacteri

21 Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in preventin

22 ells specific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the lungs, and the IFN-gamma CD

23 terium avium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vitro.

24 um smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG) in which a very high proportion of

25 expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memory-type

26 ls responding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infection and disrupt granuloma fo

27 enriched diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infection.

28 sing intradermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination as a surrogate for M.

29 conferred by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted and poorl

30 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protection agai

31 ssed in M. tuberculosis and M. bovis Bacille Calmette-Guerin (BCG), using reverse transcription-polym

32 um smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which respectively induce high an

33 acaques (SIVmac)/Mycobacterium bovis bacille Calmette-Guerin (BCG)-coinfected macaque model.

34 In Mycobacterium bovis Bacille Calmette-Guerin (BCG)-infected wild-type mice, there was

35 ly infected with Mycobacterium bovis bacille Calmette-Guerin (BCG).

36 but not the vaccine strain M. bovis bacille Calmette-Guerin (BCG).

37 activity against Mycobacterium bovis bacille Calmette-Guerin and virulent M. tuberculosis.

38 that exposure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacterium marinum to thiacetazone

39 Infection with Mycobacterium bovis bacille Calmette-Guerin resulted in approximately 10-fold-higher

40 tuberculosis and Mycobacterium bovis bacille Calmette-Guerin similarly home to established granulomas

41 enge compared with standard M. bovis bacille Calmette-Guerin vaccination.

42 tuberculosis and Mycobacterium bovis bacille Calmette-Guerin, release MVs when growing in both liquid

43 enuated form of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

44 detect antibody responses induced by bacille Calmette-Guerin (BCG) vaccination and active tuberculosi

45 thin hepatic granulomas triggered by Bacille Calmette-Guerin or Mycobacterium tuberculosis.

46 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosi

47 l Ags in the context of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T cell re

48 icial bladder cancer who have failed bacille Calmette-Guerin.

49 ries was 2.3 weeks (IQR 1.4-4.6) for bacille Calmette-Guerin (BCG); 2.4 weeks (1.2-3.3) for diphtheri

50 an effective combination therapy for bacille Calmette-Guerin failures.

51 roposed as a second-line therapy for bacille Calmette-Guerin failures.

52 une correlates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the MVA85A

53 secreting T cells when used alone in bacille Calmette-Guerin (BCG)-naive healthy volunteers.

54 bovis bloodstream infection (BSI) in bacille Calmette-Guerin (BCG)-vaccinated children with human imm

55 antigens shown previously to induce bacille Calmette-Guerin-specific gammadelta T cells.

56 Intravesical bacille Calmette-Guerin (including a maintenance regimen) should

57 of 10 of these 19 patients with live bacille Calmette-Guerin.

58 n directed against the mycobacterium bacille Calmette-Guerin (BCG).

59 The variable efficacy of Bacille Calmette Guerin (BCG) vaccination against tuberculosis h

60 Use of bacille Calmette-Guerin (BCG) as a surrogate for human Mycobacte

61 RAs in individuals with a history of Bacille Calmette-Guerin (BCG) vaccination after infancy or with

62 Approximately 100 million doses of bacille Calmette-Guerin (BCG) vaccine are given each year to pro

63 nd inhibited NO-dependent killing of bacille Calmette-Guerin by macrophages.

64 olled trials of the effectiveness of bacille Calmette-Guerin vaccine in preventing active tuberculosi

65 e, M72/AS01, in a phase IIa trial of bacille Calmette-Guerin-vaccinated, HIV-uninfected, and Mycobact

66 th environmental mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the estimat

67 d with Mycobacterium tuberculosis or bacille Calmette-Guerin have been shown to facilitate presentati

68 by infection with M. tuberculosis or bacille Calmette-Guerin, or treatment with LPS or TNF-alpha.

69 e-promastigote vaccine cocktail plus bacille Calmette-Guerin (BCG) adjuvant significantly reduced the

70 ell melanoma vaccine, Canvaxin, plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG.

71 tion involves the use of recombinant bacille Calmette-Guerin (rBCG) overexpressing protective TB anti

72 Failure to replace Bacille Calmette-Guerin vaccines with efficacious anti-tuberculo

73 ection in Mycobacterium bovis strain bacille Calmette-Guerin (BCG)-induced granulomas using an immuno

74 cterium bovis-derived vaccine strain bacille Calmette-Guerin (BCG).

75 n sharp contrast, the vaccine strain bacille Calmette-Guerin as well as RD-1 and ESAT-6 mutants of H3

76 Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy volunteers

77 We have previously established that bacille Calmette-Guerin (BCG), an attenuated form of Mycobacteri

78 erculosis every year even though the bacille Calmette Guerin (BCG) vaccine has been available for mor

79 Policies regarding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis vary grea

80 stence of therapeutic agents and the bacille Calmette-Guerin (BCG) vaccine have not significantly aff

81 r specificity in those receiving the bacille Calmette-Guerin vaccine and poor sensitivity in individu

82 Research into the bacille Calmette-Guerin vaccine demonstrated the importance of c

83 The bacille Calmette-Guerin vaccine provides very efficient protecti

84 The failure of the bacille Calmette-Guerin vaccine, synergy between AIDS and TB, an

85 ected macaques previously exposed to bacille Calmette-Guerin (BCG) were reinfected with BCG, were tre

86 The addition of interferon to bacille Calmette-Guerin has proven to be an effective combinatio

87 and existing ones improved to treat bacille Calmette-Guerin-refractory superficial bladder cancer.

88 iable efficacy of the currently used bacille Calmette-Guerin vaccine.

89 mycobacterial challenge model, using bacille Calmette-Guerin (BCG) as a surrogate for a Mycobacterium

90 The tuberculosis (TB) vaccine bacille Calmette-Guerin (BCG) is a live attenuated organism, but

91 live attenuated tuberculosis vaccine bacille Calmette-Guerin (BCG).

92 intravesical agent in patients with bacille Calmette-Guerin (BCG) -refractory transitional cell carc

93 When PMCs were stimulated with bacille Calmette-Guerin (BCG) in vitro, they expressed ICAM-1 in

94 The cells were infected with bacille Calmette-Guerin (BCG), and intracellular mycobacterial t

95 cally into macrophages infected with bacille Calmette-Guerin expressing the green fluorescent protein

96 ho receive intravesical therapy with bacille Calmette-Guerin should be considered for ongoing mainten

97 ous, DNP-modified vaccine mixed with bacille Calmette-Guerin.

98 r those who cannot be immunized with bacille Calmette-Guerin.

99 y infection with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

100 such as M. tuberculosis and M. bovis Bacille-Calmette-Guerin.

101 exposure to M. tuberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently lack the

102 had or had not been vaccinated with Bacille-Calmette Guerin (BCG).

103 Bacillus Calmette-Guerin (BCG) has been used for vaccination agai

104 Bacillus Calmette-Guerin (BCG) osteitis was more common in Finlan

105 Bacillus Calmette-Guerin (BCG) seems to have beneficial nonspecif

106 Bacillus Calmette-Guerin (BCG) vaccine is the most widely adminis

107 Bacillus Calmette-Guerin (BCG) vaccine is widely used for the pre

108 Bacillus Calmette-Guerin (BCG), the antituberculosis vaccine, loc

109 Bacillus Calmette-Guerin (BCG), the tuberculosis vaccine, is an a

110 Bacillus Calmette-Guerin-induced production of the proinflammator

111 ements, other dietary approaches, a Bacillus Calmette-Guerin trial in 1976, molecular-targeted agents

112 dder cancer (NMIBC) recurrent after bacillus Calmette-Guerin therapy is complex and further complicat

113 Multivariate analyses examined age, bacillus Calmette-Guerin (BCG) vaccination status, and sex as pre

114 Although Bacillus Calmette-Guerin (BCG) intravesical therapy is a standard

115 Although Bacillus Calmette-Guerin (BCG) vaccines against tuberculosis have

116 oth tuberculosis (TB) infection and bacillus Calmette Guerin (BCG) vaccination.

117 ip between apoptotic regulation and bacillus Calmette-Guerin (BCG) treatment in murine peritoneal exu

118 y of interventions, such as IPT and bacillus Calmette-Guerin (BCG) vaccination for preventing TB dise

119 ium tuberculosis (strain H37Rv) and bacillus Calmette-Guerin (BCG) vaccine inhibit phagosome maturati

120 ate tuberculosis susceptibility and bacillus Calmette-Guerin (BCG)-induced immunity are mostly unknow

121 that Mycobacterium tuberculosis and bacillus Calmette-Guerin infections of macaques induced expressio

122 status of index cases, the age and bacillus Calmette-Guerin vaccination status of contacts, and stud

123 r the bacteria Escherichia coli and bacillus Calmette-Guerin, which increased other DC subsets.

124 Immunomodulators such as Bacillus Calmette-Guerin and interferon are clinically active in

125 ted TLR ligands or bacteria such as bacillus Calmette-Guerin increases antitumor immune responses and

126 esistance of mice to the attenuated bacillus Calmette-Guerin vaccine strain.

127 The only vaccine available, Bacillus Calmette-Guerin (BCG), has been used since its inception

128 on after stimulation with live BCG (Bacillus Calmette-Guerin), and a second locus on chromosome regio

129 e estimated the association between bacillus Calmette-Guerin (BCG) vaccination and childhood asthma i

130 for the derivation of the M. bovis bacillus Calmette and Guerin (BCG) vaccine strain selected for an

131 ith recombinant Mycobacterium bovis bacillus Calmette Guerin (BCG) expressing the vector only (BCG-ve

132 n combined with Mycobacterium bovis bacillus Calmette Guerin (BCG) represents a potential strategy fo

133 ed 3,290 mutant Mycobacterium bovis bacillus Calmette Guerin (BCG) strains to identify genes that dec

134 ound M. avium, Mycobacterium bovis (bacillus Calmette-Guerin), and Mycobacterium tuberculosis (strain

135 munization with Mycobacterium bovis bacillus Calmette-Guerin (BCG) administered subcutaneously.

136 nes, based upon Mycobacterium bovis bacillus Calmette-Guerin (BCG) all interfere with the action of t

137 accination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) alone or as a BCG prime/Mtb72F-boo

138 owing organisms Mycobacterium bovis bacillus Calmette-Guerin (BCG) and M. tuberculosis.

139 vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) and were then challenged with viru

140 en expressed in Mycobacterium bovis bacillus Calmette-Guerin (BCG) but not when all seven phosphoryla

141 wall lipids of Mycobacterium bovis bacillus Calmette-Guerin (BCG) by coating the lipids onto 90-micr

142 ministration of Mycobacterium bovis bacillus Calmette-Guerin (BCG) continues to be a successful immun

143 In contrast, the vaccine M. bovis bacillus Calmette-Guerin (BCG) does not stimulate MMP-1 secretion

144 cobacteria since avirulent M. bovis bacillus Calmette-Guerin (BCG) fails to trigger significant expre

145 Although Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been accepted as the most effe

146 Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been used to treat bladder can

147 lular growth of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in human macrophages.

148 uberculosis and Mycobacterium bovis bacillus Calmette-Guerin (BCG) induce potent expansions of human

149 okine following Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection.

150 n during murine Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection.

151 Mycobacterium bovis bacillus Calmette-Guerin (BCG) is the only vaccine approved for p

152 vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) nor tuberculin skin test (TST) pos

153 immunized with Mycobacterium bovis bacillus Calmette-Guerin (BCG) or Mycobacterium avium.

154 ses to M. tuberculosis and M. bovis bacillus Calmette-Guerin (BCG) Pasteur in vivo and in vitro.

155 cobacterium bovis Ravenel, M. bovis bacillus Calmette-Guerin (BCG) Pasteur, and M. bovis BCG Montreal

156 the control of Mycobacterium bovis bacillus Calmette-Guerin (BCG) pleural infection in a murine mode

157 ected with live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) produced large amounts of CXCL1 an

158 accination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) remains the only prophylactic vacc

159 protocols using Mycobacterium bovis bacillus Calmette-Guerin (BCG) to prime and modified vaccinia vir

160 the failure of Mycobacterium bovis bacillus Calmette-Guerin (BCG) to protect against disease, new va

161 Mycobacterium bovis Bacillus Calmette-Guerin (BCG) use in the treatment of bladder ca

162 Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination is efficacious for new

163 dies induced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination to protect against myc

164 eover, improved Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine-induced protection was los

165 osis (Mtb), and Mycobacterium bovis bacillus Calmette-Guerin (BCG) were studied for their ability to

166 vaccine strain Mycobacterium bovis bacillus Calmette-Guerin (BCG), and it is hypothesized that these

167 ulosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is contraindicated for immunocomp

168 e only vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is largely ineffective, and ways

169 r macrophages infected with M bovis Bacillus Calmette-Guerin (BCG), M phlei, M avium 2151-rough, and

170 infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG), peaking by days 14-21 posttreatme

171 Tmt ortholog in Mycobacterium bovis Bacillus Calmette-Guerin (BCG), we show for the first time that a

172 Th1 immunity is Mycobacterium bovis bacillus Calmette-Guerin (BCG), which has been used in newborns f

173 emonstrate that Mycobacterium bovis bacillus Calmette-Guerin (BCG)-mediated TLR2 signaling-induced iN

174 istance against Mycobacterium bovis bacillus Calmette-Guerin (BCG).

175 Mycoplasma and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

176 live attenuated Mycobacterium bovis bacillus Calmette-Guerin (BCG).

177 infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

178 smegmatis) and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

179 h1 responses to Mycobacterium bovis bacillus Calmette-Guerin (BCG).

180 ven heat-killed Mycobacterium bovis bacillus Calmette-Guerin (HK-BCG) i.p. did not release PGE(2).

181 (along with the attenuated M. bovis bacillus Calmette-Guerin [BCG]), and Mycobacterium microti; incre

182 In this report, Mycobacterium bovis bacillus Calmette-Guerin and M. tuberculosis H37Ra were used as m

183 infection with Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis.

184 accination with Mycobacterium bovis bacillus Calmette-Guerin compared with control mice after infecti

185 nduced cross processing of M. bovis bacillus Calmette-Guerin expressing OVA could be circumvented by

186 hanced cross processing of M. bovis bacillus Calmette-Guerin expressing OVA, bypassing the inhibition

187 le infection by Mycobacterium bovis bacillus Calmette-Guerin failed to induce IRF-1 expression and ha

188 tuberculosis or Mycobacterium bovis bacillus Calmette-Guerin failed to induce TLR-dependent activatio

189 luenza virus or Mycobacterium bovis bacillus Calmette-Guerin had no effect.

190 infection with Mycobacterium bovis bacillus Calmette-Guerin in mice.

191 the attenuated Mycobacterium bovis bacillus Calmette-Guerin induces less PPARgamma and preferentiall

192 Following Mycobacterium bovis bacillus Calmette-Guerin infection and costimulation with IFN-gam

193 t that M. tuberculosis and M. bovis bacillus Calmette-Guerin infection down-regulated the expression

194 in response to Mycobacterium bovis bacillus Calmette-Guerin infections.

195 d nonpathogenic Mycobacterium bovis bacillus Calmette-Guerin intracellular survival, downregulated an

196 d for growth of Mycobacterium bovis bacillus Calmette-Guerin on minimal but not rich medium.

197 enuated vaccine Mycobacterium bovis bacillus Calmette-Guerin or the adoptive transfer of mycobacteria

198 ted with viable Mycobacterium bovis bacillus Calmette-Guerin or TLR ligands.

199 ith recombinant Mycobacterium bovis bacillus Calmette-Guerin overexpressing the 30-kDa antigen, C3HeB

200 ported that M. marinum and M. bovis bacillus Calmette-Guerin produce a type of spore known as an endo

201 izing mice with Mycobacterium bovis bacillus Calmette-Guerin to augment host immunity before infectio

202 ells induced by Mycobacterium bovis bacillus Calmette-Guerin vaccination.

203 inoculation of Mycobacterium bovis bacillus Calmette-Guerin vaccine in humans.

204 rculosis H37Ra, Mycobacterium bovis bacillus Calmette-Guerin, and M. kansasii) induced significantly

205 lular bacterium Mycobacterium bovis bacillus Calmette-Guerin, macrophages recovered from the peritone

206 by bcg_1279c in Mycobacterium bovis bacillus Calmette-Guerin, plays an important role in mycobacteria

207 Mycobacterium bovis bacillus Calmette-Guerin, the only vaccine available against tube

208 ition of M. tuberculosis var. bovis Bacillus Calmette-Guerin-induced p38 MAPK activity caused a marke

209 Mycobacterium bovis bacillus Calmette-Guerin-infected IL-10(-/-) mice had significant

210 isolated from the serum of M. bovis bacillus Calmette-Guerin-infected mice could also stimulate macro

211 M. bovis bacillus Calmette-Guerin-primed sanroque T cells transferred into

212 vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

213 bacterial activity against M. bovis bacillus Calmette-Guerin.

214 cus aureus, and Mycobacterium bovis bacillus Calmette-Guerin.

215 berculosis, and Mycobacterium bovis bacillus Calmette-Guerin.

216 vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

217 attenuated descendant of M. bovis, bacillus Calmette-Guerin (BCG), widely used as a vaccine against

218 nuated vaccine, Mycobacterium bovis-bacillus Calmette-Guerin as well as in mice infected i.v. with M.

219 d not only by endotoxin but also by bacillus Calmette-Guerin (BCG) and CD40 ligand and was associated

220 nd CD8+ T cell responses induced by bacillus Calmette-Guerin and a recombinant subunit protein vaccin

221 a 10.8-kDa protein not expressed by bacillus Calmette-Guerin.

222 losis comparable to that induced by bacillus Calmette-Guerin.

223 (ASI) with an autologous tumor cell-bacillus Calmette-Guerin (BCG) vaccine was conducted to determine

224 Vaccinations studied comprised Bacillus Calmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis

225 bject 1 presented with disseminated Bacillus Calmette-Guerin infection and oligoclonal T cells with n

226 apoptosis of CD4(+) T cells during bacillus Calmette-Guerin (BCG) infection of mice.

227 or cells producing IFN-gamma during bacillus Calmette-Guerin (BCG) vaccination and subsequent M. tube

228 ighly induced in macrophages during bacillus Calmette-Guerin infection.

229 fforts toward developing agents for bacillus Calmette-Guerin-refractory superficial bladder cancer co

230 es in the development of agents for bacillus Calmette-Guerin-refractory superficial bladder cancer.

231 he underwent cystoprostatectomy for bacillus Calmette-Guerin-refractory, high-grade noninvasive UC.

232 differentiation of Th17 cells from bacillus Calmette-Guerin-challenged (BCG-challenged) lung CD4+ T

233 e observed in livers and lungs from bacillus Calmette-Guerin-infected humanized mice but not in nonhu

234 4 expression by CD4(+) T cells from bacillus Calmette-Guerin-vaccinated mice and show that high-quali

235 Furthermore, bacillus Calmette-Guerin-vaccinated IFN-gamma-deficient mice exhi

236 is Ags Ag85A, Ag85B, and TB10.4, in bacillus Calmette-Guerin (BCG)-primed or unprimed rhesus macaques

237 th factor Vegf-c is up-regulated in Bacillus Calmette-Guerin- and Mycobacterium tuberculosis-induced

238 target, also lowered intracellular Bacillus Calmette-Guerin levels in mammary epithelial cancer MCF-

239 for patients who fail intravesical bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder can

240 mbination therapy with intravesical bacillus Calmette-Guerin (BCG) plus IFN-alpha for superficial bla

241 r cancer refractory to intravesical bacillus Calmette-Guerin (BCG) therapy and refusing a cystectomy

242 patients according to intravesical Bacillus Calmette-Guerin (BCG) treatment status: no BCG, inductio

243 ta supports the use of intravesical Bacillus Calmette-Guerin (including a maintenance regimen) for th

244 ata support the use of intravesical bacillus Calmette-Guerin (including a maintenance regimen) for th

245 rastriatal injection of heat-killed bacillus Calmette-Guerin (BCG) and subsequent activation using an

246 th lymphadenitis caused by the live Bacillus Calmette-Guerin (BCG) vaccine.

247 n response to stimulation with live bacillus Calmette-Guerin (BCG; LOD score, 3.81; P = 1.40 x 10(-5)

248 Although maintenance bacillus Calmette-Guerin (BCG) for at least 1 year has been recom

249 e considered the childhood measles, bacillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, an

250 lomas from M. tuberculosis- but not bacillus Calmette-Guerin-infected humanized mice.

251 to react with Mtb-infected, but not bacillus Calmette-Guerin-infected, targets.

252 r a single dose (1 x 10(5) CFUs) of bacillus Calmette-Guerin (BCG) or Mycobacterium vaccae via nasal

253 al infection, recombinant clones of bacillus Calmette-Guerin (BCG) were engineered to express the nat

254 ripheral blood mononuclear cells of bacillus Calmette-Guerin (BCG)-vaccinated individuals with live M

255 of PBMCs with the Moreau strain of bacillus Calmette-Guerin but not after infection with other strai

256 he primary attenuating mechanism of bacillus Calmette-Guerin is the loss of cytolytic activity mediat

257 H65 gave protection at the level of bacillus Calmette-Guerin, and the fusion protein exhibited high p

258 ciated carcinoma in situ, nonuse of bacillus Calmette-Guerin, tumor size > 3 cm, and older age; HRs f

259 Granulomas of bacillus Calmette-Guerin-infected humanized mice administered wit

260 are more effective than the present bacillus Calmette-Guerin (BCG) vaccine.

261 us pneumoniae, Helicobacter pylori, bacillus Calmette-Guerin, and Mycobacterium tuberculosis) in a mu

262 tion, immunization with recombinant bacillus Calmette-Guerin (BCG) expressing RSV nucleoprotein preve

263 CV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tubercul

264 fore and after primary or secondary bacillus Calmette-Guerin (BCG) vaccination were assessed for Ab r

265 duced by Mycobacterium bovis strain bacillus Calmette-Guerin (BCG) in mice.

266 model of Mycobacterium bovis strain bacillus Calmette-Guerin (BCG) infection we studied the extent of

267 that a more effective vaccine than bacillus Calmette-Guerin is urgently needed.

268 In this study, we found that bacillus Calmette-Guerin (BCG) and viable M. tuberculosis as well

269 Studies have suggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of

270 Evidence suggests that bacillus Calmette-Guerin is the most effective intravesical thera

271 The Bacillus Calmette - Guerin (BCG) vaccine provides a critical but

272 The bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis is u

273 Although the bacillus Calmette-Guerin (BCG) vaccine is widely used, it has maj

274 immunotherapy instillation with the bacillus Calmette-Guerin (BCG) vaccine.

275 atients had previously received the bacillus Calmette-Guerin (BCG) vaccine; among this vaccinated gro

276 Mycobacterium tuberculosis and the bacillus Calmette-Guerin can be tracked directly in the lungs of

277 among persons who had received the Bacillus Calmette-Guerin vaccine in households with and without a

278 ate) or placebo together with their Bacillus Calmette-Guerin vaccination.

279 er (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience diseas

280 ulent M. tuberculosis comparable to bacillus Calmette-Guerin immunization.

281 n mediating Th1 immune responses to Bacillus Calmette-Guerin infection in vivo.

282 ated as alternatives to traditional Bacillus Calmette-Guerin needles and syringes for the administrat

283 lable vaccine against tuberculosis, bacillus Calmette Guerin (BCG), has traditionally been viewed not

284 ccines revealed that currently used bacillus Calmette-Guerin strains vary in their ability to affect

285 tent than the current live vaccine, bacillus Calmette-Guerin (BCG), is desperately needed.

286 cted a novel breast cancer vaccine, Bacillus Calmette-Guerin (BCG)-hIL2MUC1, that consists of BCG and

287 he majority of Danish patients were bacillus Calmette-Guerin (Mycobacterium bovis BCG) vaccinated (CD

288 While bacillus Calmette-Guerin vaccination plays an important role in r

289 the population of patients for whom bacillus Calmette-Guerin (BCG) has failed, the type of failure (B

290 When monkeys were immunized with bacillus Calmette-Guerin (BCG) and then boosted with Mtb72F in AS

291 n (KLH) as a carrier and given with Bacillus Calmette-Guerin (BCG) as an adjuvant, elicited HMW-MAA-s

292 Vaccination with Bacillus Calmette-Guerin (BCG) has been shown to reduce the sever

293 ldren are routinely vaccinated with bacillus Calmette-Guerin (BCG) in areas of the world where worm i

294 apy (IPT) before revaccination with bacillus Calmette-Guerin (BCG) in healthy, tuberculin skin test-p

295 negative IGRAs was associated with bacillus Calmette-Guerin (BCG) vaccination (odds ratio: 25.1 [95%

296 n a mouse model of vaccination with bacillus Calmette-Guerin (BCG), followed by challenge with virule

297 s comparable to those achieved with bacillus Calmette-Guerin vaccination.

298 The Danish Calmette Study is a multicenter randomized trial conduct

299 The Danish Calmette Study was conducted 2012-2015.

300 radiated autologous tumor cells admixed with Calmette-Guerin bacillus.